SCHEMBL1697141

SCHEMBL1697141

O=c1[nH]c(=O)c2c(nc(-c3c[nH]nc3Cc3ccccn3)n2CC2CC2)[nH]1

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NR3C1 P04150 4/20 0.39
DPP4 P27487 1/20 0.37
TSHR P16473 1/20 0.36
PDE9A O76083 1/20 0.35
GABRA1 P14867 1/20 0.34
GABRA5 P31644 1/20 0.34
PNP P00491 1/20 0.32
GPR39 O43194 1/20 0.31
BRDT Q58F21 1/20 0.31
NOD1 Q9Y239 1/20 0.31
LMNA P02545 1/20 0.31
KDM4E B2RXH2 1/20 0.31
MAPT P10636 1/20 0.31
PDE5A O76074 1/20 0.30
PDE3B Q13370 1/20 0.30
PDE3A Q14432 1/20 0.30
TPH1 P17752 2/20 0.30
TPH2 Q8IWU9 2/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4014400 0.81 ADORA2A (0.41) DPP4
SCHEMBL4016883 0.66 TPH1 (0.44) TSHRKDM4EMAPTTPH1TPH2
SCHEMBL4016181 0.66 MEN1 (0.42) DPP4TSHRNOD1LMNAMAPT
SCHEMBL5509419 0.65 ADORA3 (0.44) NR3C1TSHRLMNAKDM4EMAPT
SCHEMBL5061625 0.65 TPH1 (0.48) KDM4EPDE5ATPH1TPH2
SCHEMBL4016921 0.64 ADORA2B (0.41) NR3C1NOD1LMNATPH1TPH2
SCHEMBL4019325 0.63 LMNA (0.42) NR3C1LMNAKDM4ETPH1TPH2
SCHEMBL4295147 0.61 MAOB (0.40) NR3C1LMNATPH1TPH2
SCHEMBL25906471 0.60 TSHR (0.48) TSHRPNPLMNAMAPT
SCHEMBL24559366 0.59 GRIN1 (0.35) LMNAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2595630-A1 USE OF A2B ADENOSINE RECEPTOR ANTAGONISTS FOR TREATING PULMONARY HYPERTENSION Gilead Sciences, Inc. (US) 2013-05-29 EP claimed
WO-2012003220-A1 USE OF A2B ADENOSINE RECEPTOR ANTAGONISTS FOR TREATING PULMONARY HYPERTENSION GILEAD SCIENCES, INC. (US) 2012-01-05 WO claimed
EP-2694074-A1 USE OF A2B ADENOSINE RECEPTOR ANTAGONISTS FOR TREATING HEART FAILURE AND ARRHYTHMIA IN POST-MYOCARDIAL INFARCTION PATIENTS Gilead Sciences, Inc. (US) 2014-02-12 EP disclosed
EP-2595630-A1 USE OF A2B ADENOSINE RECEPTOR ANTAGONISTS FOR TREATING PULMONARY HYPERTENSION Gilead Sciences, Inc. (US) 2013-05-29 EP disclosed
WO-2012154340-A1 USE OF A2B ADENOSINE RECEPTOR ANTAGONISTS FOR TREATING HEART FAILURE AND ARRHYTHMIA IN POST-MYOCARDIAL INFARCTION PATIENTS GILEAD SCIENCES, INC. (US) 2012-11-15 WO disclosed
WO-2012003220-A1 USE OF A2B ADENOSINE RECEPTOR ANTAGONISTS FOR TREATING PULMONARY HYPERTENSION GILEAD SCIENCES, INC. (US) 2012-01-05 WO disclosed